First-line treatment in lymphomatoid papulosis: a retrospective multicentre study

• DOI: 10.1111/ced.13256
• Publication Date: 2017-10-10T01:42:39Z
• Authors: R. Fernández-de-Misa; B. Hernández-Machín; O. Servitje; F. Valentí-Medina; L. Maroñas-Jiménez; P. L. Ortiz-Romero; J. Sánchez Schmidt; R. M. Pujol; F. Gallardo; I. Pau-Charles; M. P. García Muret; S. Pérez Gala; C. Román; J. Cañueto; L. Blanch Rius; R. Izu; A. Ortiz-Brugués; R. M. Martí; M. Blanes; M. Morillo; P. Sánchez; Y. Peñate; J. Bastida; A. Pérez Gil; I. Lopez-Lerma; C. Muniesa; T. Estrach
• Keywords: Lymphomatoid papulosis

Data regarding response to treatment in lymphomatoid papulosis (LyP) are scarce.To assess the daily clinical practice approach LyP and first-line treatments.This was a retrospective study enrolling 252 patients with LyP.Topical steroids, methotrexate phototherapy were most common treatments, prescribed for 35%, 20% 14% of patients, respectively. Complete (CR) achieved 48% treated patients. Eczematous lesions significantly increased relative risk (RR) not achieving CR (RR = 1.76; 95% CI 1.16-2.11). Overall median time 10 months (95% 6-13 months), 78% complete responders showed cutaneous relapse; both results similar all groups (P > 0.05). estimated disease-free survival (DFS) 11 9-13 months) but DFS 23 10-36 months; P < 0.03). Having Type A variant 2.04; 0.96-4.30) receiving other than 5.33; 0.84-33.89) associated early relapse. Of 31 (13%) had mycosis fungoides unrelated therapeutic approach, type or T-cell receptor clonality.Current epidemiological, pathological data support previous results. Topical frequently treatments. Although relapse rates do differ between them, achieves longer DFS. Presence use topical steroid an